View this message in your internet browser.
Renal Anemia in Chronic Kidney Disease (CKD): Following the Omontys Recall
—A Webinar from Decision Resources Group
Join Decision Resources Group for a webinar on Renal Anemia in Chronic Kidney Disease (CKD): Following the Omontys Recall
This webinar will be presented two times:
After nearly ten months on the U.S. market, Affymax/Takeda voluntarily recalled their once-monthly ESA Omontys (peginesatide) for dialysis patients on February 23, 2013 due to safety concerns. At the same time, there are several new products in the late stage clinical pipeline to treat renal anemia and iron deficiency. Additionally, there are new phosphate binders in development to not only treat bone and mineral metabolism imbalance, but to also potentially reduce the need for Erythropoiesis-Stimulating Agents (ESAs) and IV iron.
There are over 415,000 dialysis and 29 million CKD non-dialysis patients in the U.S. alone, creating a large potential for treatment therapies in this patient population. Many of these patients are treated for renal anemia and iron deficiency, with currently available agents: ESAs and IV iron. (Source: United States Renal Data System - 2012 Annual Data Report)
In this webinar DRG Director, Rob Dubman and Analyst, Matthew Scutcher, Ph.D., will provide an overview of the CKD market with a focus on renal anemia and address the following questions:
A live Q&A session will be held following the presentation.
Please register by 8 a.m. U.S. Eastern Time on April 24 in order to attend the event.
About the Speakers
Rob Dubman is the director of nephrology at BioTrends Research Group. Prior to joining BioTrends, Mr. Dubman has worked in various market research roles within several biopharmaceuticals and medical device organizations, including Bristol-Myers Squibb (Oncology Therapeutics Network and medical imaging), Genzyme and Smith & Nephew. At Genzyme, Mr. Dubman managed many market research projects in Genzyme’s cardio-metabolic and renal business units. He has a Bachelor of Science degree from George Washington University and a Masters of Business Administration from Bentley University.